ETF Holdings Breakdown of SYRE

SYRE institutional holdings

Date	ETF ISIN/Name	Num Shares	Book value
2025-10-20	IE00B3VWM098 (iShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc)	24,846	USD 583,633 4.3%
2025-10-20	IE00BYXG2H39 (iShares Nasdaq US Biotechnology UCITS ETF USD (Acc))	37,992	USD 892,432
2025-10-20	IE00BDZVHG35 (iShares Nasdaq US Biotechnology UCITS ETF USD (Dist))	37,992	USD 892,432
2025-10-20	IE00BF4RFH31 (iShares MSCI World Small Cap UCITS ETF USD (Acc))	33,502	USD 786,962
2025-10-20	IE000T9EOCL3 (iShares MSCI World Small Cap ESG Enhanced UCITS ETF USD (Acc))	1,081	USD 25,393
Total =		135,413	USD 3,180,852

Book value of shares is calculated on the adjusted close price of each day (row).

News associated with SYRE

Spyre Therapeutics (NASDAQ:SYRE) Upgraded by Wall Street Zen to “Hold” Rating

Wall Street Zen upgraded shares of Spyre Therapeutics (NASDAQ:SYRE – Free Report) from a sell rating to a hold rating in a research report sent to investors on Monday. Separately, Wedbush reiterated an “outperform” rating and issued a $65.00 price target on shares of Spyre Therapeutics in a research note on Wednesday, August 6th. Two […] - 2025-09-09 02:57:04

Brokerages Set Spyre Therapeutics, Inc. (NASDAQ:SYRE) Price Target at $53.40

Spyre Therapeutics, Inc. (NASDAQ:SYRE – Get Free Report) has been given a consensus recommendation of “Buy” by the seven analysts that are currently covering the firm, Marketbeat reports. Five investment analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. The average 12-month target price […] - 2025-09-08 02:32:51

Spyre Therapeutics, Inc. (NASDAQ:SYRE) Receives $53.40 Average PT from Analysts

Spyre Therapeutics, Inc. (NASDAQ:SYRE – Get Free Report) has been given an average recommendation of “Buy” by the seven research firms that are covering the firm, MarketBeat.com reports. Five equities research analysts have rated the stock with a buy rating and two have issued a strong buy rating on the company. The average 1 year […] - 2025-08-14 02:31:05

XTX Topco Ltd Acquires Shares of 28,499 Spyre Therapeutics, Inc. (NASDAQ:SYRE)

XTX Topco Ltd acquired a new stake in Spyre Therapeutics, Inc. (NASDAQ:SYRE – Free Report) in the first quarter, Holdings Channel reports. The institutional investor acquired 28,499 shares of the company’s stock, valued at approximately $460,000. A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the […] - 2025-08-08 04:38:55

Victory Capital Management Inc. Lowers Holdings in Spyre Therapeutics, Inc. (NASDAQ:SYRE)

Victory Capital Management Inc. decreased its holdings in Spyre Therapeutics, Inc. (NASDAQ:SYRE – Free Report) by 6.1% in the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 251,846 shares of the company’s stock after selling 16,230 shares during the quarter. Victory Capital Management Inc.’s […] - 2025-07-28 05:02:49

Spyre Therapeutics, Inc. (NASDAQ:SYRE) Given Average Recommendation of “Buy” by Analysts

Spyre Therapeutics, Inc. (NASDAQ:SYRE – Get Free Report) has earned an average rating of “Buy” from the seven ratings firms that are currently covering the company, Marketbeat Ratings reports. Five analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. The average 12 month price […] - 2025-07-17 05:10:58

122,153 Shares in Spyre Therapeutics, Inc. (NASDAQ:SYRE) Acquired by Universal Beteiligungs und Servicegesellschaft mbH

Universal Beteiligungs und Servicegesellschaft mbH purchased a new stake in Spyre Therapeutics, Inc. (NASDAQ:SYRE – Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm purchased 122,153 shares of the company’s stock, valued at approximately $2,844,000. Universal Beteiligungs und Servicegesellschaft mbH owned 0.24% […] - 2025-06-03 05:35:02

Spyre Therapeutics, Inc. (NASDAQ:SYRE) Shares Acquired by MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.

MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in shares of Spyre Therapeutics, Inc. (NASDAQ:SYRE – Free Report) by 4.2% in the fourth quarter, HoldingsChannel.com reports. The firm owned 22,741 shares of the company’s stock after acquiring an additional 916 shares during the quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.’s holdings in Spyre Therapeutics […] - 2025-05-30 04:48:57

Analysts Set Spyre Therapeutics, Inc. (NASDAQ:SYRE) PT at $49.57

Shares of Spyre Therapeutics, Inc. (NASDAQ:SYRE – Get Free Report) have been assigned a consensus recommendation of “Buy” from the ten brokerages that are presently covering the stock, Marketbeat Ratings reports. Eight research analysts have rated the stock with a buy recommendation and two have given a strong buy recommendation to the company. The average […] - 2025-05-06 02:32:52

Spyre Therapeutics, Inc. (NASDAQ:SYRE) Shares Acquired by Barclays PLC

Barclays PLC lifted its position in Spyre Therapeutics, Inc. (NASDAQ:SYRE – Free Report) by 16.7% in the fourth quarter, Holdings Channel reports. The firm owned 123,071 shares of the company’s stock after acquiring an additional 17,604 shares during the period. Barclays PLC’s holdings in Spyre Therapeutics were worth $2,866,000 as of its most recent filing […] - 2025-04-30 05:15:05

Legal & General Group Plc Has $873,000 Position in Spyre Therapeutics, Inc. (NASDAQ:SYRE)

Legal & General Group Plc grew its holdings in Spyre Therapeutics, Inc. (NASDAQ:SYRE – Free Report) by 14.8% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 37,490 shares of the company’s stock after purchasing an additional 4,824 shares during the quarter. […] - 2025-04-28 04:56:53

Vanguard Group Inc. Purchases 330,553 Shares of Spyre Therapeutics, Inc. (NASDAQ:SYRE)

Vanguard Group Inc. increased its position in shares of Spyre Therapeutics, Inc. (NASDAQ:SYRE – Free Report) by 13.1% in the 4th quarter, HoldingsChannel reports. The fund owned 2,846,473 shares of the company’s stock after acquiring an additional 330,553 shares during the period. Vanguard Group Inc. owned approximately 0.06% of Spyre Therapeutics worth $66,266,000 as of […] - 2025-04-11 05:40:57

Spyre Therapeutics, Inc. (NASDAQ:SYRE) Receives $50.33 Average Price Target from Brokerages

Shares of Spyre Therapeutics, Inc. (NASDAQ:SYRE – Get Free Report) have received an average rating of “Buy” from the ten analysts that are covering the stock, Marketbeat.com reports. Eight analysts have rated the stock with a buy recommendation and two have issued a strong buy recommendation on the company. The average 12 month target price […] - 2025-04-11 02:54:51

Corebridge Financial Inc. Sells 1,299 Shares of Spyre Therapeutics, Inc. (NASDAQ:SYRE)

Corebridge Financial Inc. lowered its stake in shares of Spyre Therapeutics, Inc. (NASDAQ:SYRE – Free Report) by 7.0% in the fourth quarter, according to its most recent 13F filing with the SEC. The fund owned 17,213 shares of the company’s stock after selling 1,299 shares during the period. Corebridge Financial Inc.’s holdings in Spyre Therapeutics […] - 2025-04-10 04:49:04

Spyre Therapeutics, Inc. (NASDAQ:SYRE) Shares Acquired by Wellington Management Group LLP

Wellington Management Group LLP increased its position in shares of Spyre Therapeutics, Inc. (NASDAQ:SYRE – Free Report) by 6.5% during the fourth quarter, Holdings Channel.com reports. The fund owned 1,604,508 shares of the company’s stock after acquiring an additional 97,308 shares during the quarter. Wellington Management Group LLP’s holdings in Spyre Therapeutics were worth $37,353,000 […] - 2025-04-07 06:35:09

Schroder Investment Management Group Takes $2.56 Million Position in Spyre Therapeutics, Inc. (NASDAQ:SYRE)

Schroder Investment Management Group bought a new position in Spyre Therapeutics, Inc. (NASDAQ:SYRE – Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm bought 113,620 shares of the company’s stock, valued at approximately $2,561,000. Schroder Investment Management Group owned about 0.22% of Spyre […] - 2025-04-07 05:10:58

Natixis Advisors LLC Invests $403,000 in Spyre Therapeutics, Inc. (NASDAQ:SYRE)

Natixis Advisors LLC bought a new position in Spyre Therapeutics, Inc. (NASDAQ:SYRE – Free Report) during the fourth quarter, Holdings Channel reports. The firm bought 17,300 shares of the company’s stock, valued at approximately $403,000. Several other large investors have also added to or reduced their stakes in SYRE. Barclays PLC increased its holdings in […] - 2025-03-28 06:04:54

Wolfe Research Initiates Coverage on Spyre Therapeutics (NASDAQ:SYRE)

Wolfe Research assumed coverage on shares of Spyre Therapeutics (NASDAQ:SYRE – Get Free Report) in a research report issued on Tuesday, Marketbeat.com reports. The brokerage set an “outperform” rating and a $27.00 price target on the stock. Wolfe Research’s price objective suggests a potential upside of 46.74% from the company’s previous close. Several other equities […] - 2025-03-20 04:22:57

Spyre Therapeutics, Inc. (NASDAQ:SYRE) Receives Average Rating of “Buy” from Analysts

Spyre Therapeutics, Inc. (NASDAQ:SYRE – Get Free Report) has been assigned a consensus recommendation of “Buy” from the eight ratings firms that are presently covering the firm, Marketbeat Ratings reports. Seven equities research analysts have rated the stock with a buy recommendation and one has issued a strong buy recommendation on the company. The average […] - 2025-03-14 04:25:02

Back to Listing

Disclaimer